What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Bovine Respiratory Disease Complex: Bacterial Pathogens, Advanced Diagnostics, and Integrated Management

Bovine Respiratory Disease Complex (BRDC) represents the most economically significant infectious disease syndrome affecting feedlot cattle and dairy operations worldwide. This multifactorial condition results from the interplay of host stress, viral priming, and bacterial infection of the lower respiratory tract. While viral pathogens including bovine respiratory syncytial virus, bovine coronavirus, and bovine adenovirus contribute to initial epithelial damage, the ultimate clinical manifestation and mortality are driven by bacterial pathogens. This article provides an exhaustive examination of the primary bacterial agents involved in BRDC, with specific emphasis on Mannheimia haemolytica, Pasteurella multocida, and Mycoplasma bovis. The diagnostic landscape, particularly the role of rapid PCR panels and antimicrobial susceptibility testing, is discussed in depth. Management strategies incorporating antimicrobial stewardship, vaccination protocols, and biosecurity measures are evaluated based on current evidence.

Key Bacterial Pathogens in BRDC

Bacterial pneumonia in cattle typically follows viral or environmental compromise of the pulmonary defense mechanisms. The normal bovine respiratory tract harbors a commensal microbiota that includes potentially pathogenic species. Disease occurs when these organisms gain access to the lower airways and proliferate under conditions of impaired mucociliary clearance and suppressed alveolar macrophage activity. Three bacterial species account for the majority of BRDC cases.

Mannheimia haemolytica

Mannheimia haemolytica (formerly Pasteurella haemolytica biotype A serotype 1) is the most frequently isolated bacterial pathogen from acute fibrinous pneumonia in cattle [1, 2]. This Gram-negative coccobacillus produces a potent leukotoxin (LktA) belonging to the RTX (repeats-in-toxin) family. Leukotoxin specifically targets bovine leukocytes and platelets, inducing apoptosis and necrosis in alveolar macrophages and neutrophils [3]. The release of proinflammatory cytokines and lysosomal enzymes following leukotoxin-mediated cell death amplifies pulmonary inflammation, leading to the characteristic fibrinous pleuropneumonia.

Lipopolysaccharide (LPS) from M. haemolytica contributes to endotoxin-mediated shock and vascular leakage [4]. The bacterium also expresses surface adhesins such as filamentous hemagglutinin (FhaB) and autotransporter proteins that facilitate colonization of the respiratory epithelium [5]. Capsular polysaccharide provides resistance to phagocytosis. Strains of serotype A1 are heavily encapsulated and associated with severe clinical disease, while serotype A2 strains are more commonly recovered from clinically healthy carriers [6].

Pasteurella multocida

Pasteurella multocida is a commensal organism of the bovine upper respiratory tract and nasopharynx that can act as an opportunistic pathogen in BRDC. It is more commonly associated with bronchopneumonia rather than the fibrinous pleuropneumonia typical of M. haemolytica [7]. Capsular serogroups A and D predominate in bovine respiratory isolates, with capsular hyaluronic acid serving as an antiphagocytic factor [8].

The primary virulence factors of P. multocida include the polysaccharide capsule, LPS, and a dermonecrotic toxin (PMT) that modulates host cell signaling through G protein activation [9]. PMT stimulates osteoclast activity and may contribute to turbinate atrophy in atrophic rhinitis but its role in lower respiratory disease remains incompletely characterized. P. multocida also produces sialidases that degrade host mucins, facilitating bacterial access to the epithelial surface [10]. In recent years, the prevalence of P. multocida in BRDC outbreaks has increased, possibly due to selective pressure from routine metaphylactic antimicrobial use that differentially suppresses M. haemolytica [11].

Mycoplasma bovis

Mycoplasma bovis is a cell wall deficient bacterium of the class Mollicutes and a major contributor to chronic, treatment-resistant pneumonia in cattle [12]. This pathogen is additionally associated with arthritis, otitis media, mastitis, and keratoconjunctivitis. M. bovis lacks a cell wall, rendering it intrinsically resistant to beta-lactam antimicrobials and limiting the efficacy of cell wall active agents [13].

Pathogenesis involves adherence to ciliated respiratory epithelium via variable surface lipoproteins (Vsps) that undergo antigenic variation, allowing immune evasion [14]. The induction of a strong, but ineffective, Th2-biased humoral response contributes to immunopathology [15]. M. bovis produces hydrogen peroxide and superoxide radicals as byproducts of metabolism, causing oxidative damage to host tissues [16]. The organism also secretes a nuclease that degrades neutrophil extracellular traps (NETs), further impairing host clearance mechanisms [17]. Chronic infection is characterized by the formation of caseonecrotic lesions within lung parenchyma, often with central areas of coagulative necrosis surrounded by a capsule of granulation tissue [18].

Diagnostic Approaches for BRDC Bacterial Pathogens

Accurate and timely diagnosis of the bacterial etiology in BRDC is essential for directing appropriate antimicrobial therapy and implementing control measures. Traditional culture based methods remain useful but have been increasingly supplemented or replaced by molecular techniques.

Culture and Biochemical Identification

Standard aerobic culture of transtracheal wash (TTW) or bronchoalveolar lavage (BAL) fluid on blood agar and MacConkey agar allows isolation of M. haemolytica and P. multocida [19]. M. bovis requires specialized media such as Hayflicks or Friis medium supplemented with sterol, and incubation in a 5% carbon dioxide atmosphere for 3 to 10 days [20]. Colony morphology, Gram stain characteristics, and biochemical profiles (e.g., oxidase, catalase, carbohydrate fermentation) provide preliminary identification. M. haemolytica typically yields large, mucoid colonies with a characteristic sweet odor. P. multocida colonies are smaller and non-hemolytic. M. bovis produces characteristic fried-egg colonies on solid media.

Culture based methods have several limitations. Turnaround times of 48 to 72 hours are incompatible with acute clinical decision making. The sensitivity of culture for M. bovis is particularly poor due to its fastidious growth requirements and the presence of culture inhibitors in clinical samples [21]. Moreover, prior antimicrobial administration rapidly reduces culture yield.

Molecular Diagnostics: Rapid PCR Panels

Real time PCR assays have transformed the diagnosis of BRDC by enabling simultaneous detection of multiple bacterial and viral targets within a two hour window [22, 23]. Multiplex PCR panels targeting M. haemolytica, P. multocida, M. bovis, Histophilus somni, and common viral pathogens (bovine respiratory syncytial virus, bovine coronavirus, bovine adenovirus, bovine viral diarrhea virus) are commercially available as laboratory developed tests [24].

PCR offers superior sensitivity over culture, particularly for M. bovis detection. Quantitative PCR (qPCR) can provide semiquantitative estimates of bacterial load, which may help differentiate colonization from active infection [25]. The limit of detection for M. haemolytica by qPCR is approximately 10 colony forming units per reaction [26]. For M. bovis, PCR based detection yields significantly higher positivity rates than culture, with studies reporting agreement between the two methods of only 60% to 70% in field samples [27].

Sample selection is critical for PCR based diagnosis. Deep nasal swabs (DNS) collected from the nasopharynx using guarded swabs show moderate agreement with BAL fluid for M. haemolytica and P. multocida detection, but poor agreement for M. bovis [28]. TTW and BAL remain the specimens of choice for accurate detection of lower respiratory tract involvement. The Feline Upper Respiratory Tract Infection Complex: Multiplex PCR Panel Interpretation and Treatment Algorithms provides a comparative framework for understanding multiplex PCR utility in respiratory disease diagnosis across species.

Antimicrobial Susceptibility Testing

The global emergence of antimicrobial resistance (AMR) among BRDC pathogens necessitates routine susceptibility testing to guide therapy [29, 30]. Disk diffusion and broth microdilution methods standardized by the Clinical and Laboratory Standards Institute (CLSI) are used for M. haemolytica and P. multocida [31]. MIC determination is preferred for M. bovis due to its slow growth, and specific CLSI guidelines are available for this organism.

Resistance to tetracyclines, macrolides, and florfenicol has been documented in M. haemolytica and P. multocida isolates from North America and Europe [32, 33]. The prevalence of multidrug resistant isolates is concerning, with some studies reporting resistance to three or more antimicrobial classes in over 30% of M. haemolytica isolates [34]. For M. bovis, resistance to macrolides and fluoroquinolones is increasingly reported, and there is evidence of cross resistance among macrolide class representatives [35].

Genotypic resistance prediction using targeted sequencing of resistance genes (e.g., erm(42), msr(E)-mph(E), tet(H), floR) or whole genome sequencing (WGS) is gaining traction as a supplement to phenotypic testing [36, 37]. WGS based prediction of AMR in BRDC pathogens shows high concordance with broth microdilution for most antimicrobial classes, with positive predictive values exceeding 95% for macrolide resistance in M. haemolytica [38]. These approaches allow earlier resistance profiling and can be integrated with phylogenetic analyses to track transmission of resistant clones.

The relationship between AMR in livestock and human health is a critical aspect of the One Health framework, as detailed in Antimicrobial Resistance in Livestock-Associated Staphylococcus aureus: Genomic Epidemiology and One Health Implications. Although direct transmission of BRDC pathogens to humans is rare, the resistance determinants carried by these bacteria can be horizontally transferred to zoonotic agents.

Management Strategies for BRDC

The management of BRDC requires a multifaceted approach that integrates antimicrobial therapy, vaccination, environmental modifications, and biosecurity measures. Antimicrobial stewardship principles must be balanced against the need for rapid therapeutic intervention in acutely ill cattle.

Antimicrobial Therapy

First line antimicrobial agents for acute BRDC include the macrolides (tulathromycin, gamithromycin, tildipirosin), florfenicol, tetracyclines (oxytetracycline), and fluoroquinolones (enrofloxacin, danofloxacin) [39]. Selection should be based on local susceptibility patterns and the likelihood of M. bovis involvement, as this pathogen is intrinsically resistant to beta-lactams and sulfonamides.

Metaphylactic administration of long acting antimicrobials to high risk cattle at arrival to the feedlot has been widely practiced to reduce BRDC morbidity [40]. However, this practice is increasingly scrutinized due to selection pressure for AMR. Targeted metaphylaxis based on risk scoring and diagnostic screening using rapid PCR panels may allow more judicious use of antimicrobials [41]. For animals diagnosed with BRDC, early treatment within the first 24 hours of clinical signs significantly improves outcomes, with better response rates and lower case fatality.

Vaccination

Commercial vaccines are available against M. haemolytica (including leukotoxin toxoid vaccines), P. multocida, and M. bovis. M. haemolytica vaccines are the most widely utilized and have demonstrated reductions in morbidity and mortality in feedlot trials [42]. Multivalent killed vaccines containing bacterins and leukotoxin toxoid are commonly administered at processing. Modified live virus vaccines against viral components of BRDC are also integral to prevention programs.

The efficacy of M. bovis vaccines has been inconsistent [43]. Autogenous vaccines prepared from farm specific isolates may offer improved protection but require customized production. The timing of vaccination relative to stress events such as weaning, transport, and commingling is critical. Administration should occur at least two to three weeks prior to anticipated exposure to allow development of a protective immune response.

Environmental and Biosecurity Measures

Management practices that reduce stress and limit pathogen transmission are essential for BRDC control. These include:

Proper ventilation in confinement housing to reduce airborne bacterial load and ammonia concentration.
Avoidance of overstocking to minimize nose to nose contact and competition for feed.
Nutritional management to ensure adequate energy and protein intake, particularly during the receiving period.
Implementation of all in/all out housing systems where feasible.
Quarantine of newly introduced cattle for at least 21 days.
Vaccination of replacement heifers and source herds to reduce pathogen introduction.

Diagnostic Workflow for BRDC

The following mermaid diagram illustrates an evidence based diagnostic algorithm for BRDC incorporating rapid PCR testing and antimicrobial susceptibility assessment.

flowchart TD
    A[Acute respiratory disease in feedlot or dairy calf], > B[Clinical examination<br>Fever, nasal discharge, dyspnea, depression]
    B, > C{Respiratory signs < 48 hours?}
    C, Yes, > D[Collect deep nasal swab<br>or transtracheal wash]
    C, No, > E[Collect bronchoalveolar lavage fluid]
    D, > F[Rapid multiplex PCR panel:<br>M. haemolytica, P. multocida, M. bovis, H. somni, viral targets]
    E, > F
    F, > G{Positive for bacterial pathogen?}
    G, Yes, > H[Submit isolate or sample for AST<br>Disk diffusion or broth microdilution]
    G, No, > I[Consider non-infectious causes<br>or less common pathogens]
    H, > J[Select targeted antimicrobial<br>based on susceptibility profile]
    J, > K[Reassess clinical response at 48-72 hours]
    K, > L{Clinical improvement?}
    L, Yes, > M[Complete course, monitor for relapse]
    L, No, > N[Repeat PCR and AST;<br>consider M. bovis involvement]
    N, > O[Adjust therapy<br>e.g., switch to fluoroquinolone or mycoplasma-active agent]
    O, > K

Conclusion

Bovine Respiratory Disease Complex remains a formidable challenge for the cattle industry, with bacterial pathogens Mannheimia haemolytica, Pasteurella multocida, and Mycoplasma bovis at the forefront of disease pathogenesis. Advances in molecular diagnostics, particularly multiplex real time PCR panels, have enabled rapid and accurate detection of these agents, facilitating earlier and more targeted antimicrobial interventions. Antimicrobial susceptibility testing, both phenotypic and genotypic, is essential to combat the growing threat of resistance. An integrated management strategy combining rational antimicrobial use, effective vaccination, and stress reducing husbandry practices offers the best opportunity to reduce BRDC morbidity and mortality while preserving antimicrobial efficacy for future generations.

References

[1] Rice JA, Carrasco-Medina L, Hodgins DC, et al. Mannheimia haemolytica and bovine respiratory disease. Vet Clin North Am Food Anim Pract. 2010;26(2):245-267.

[2] Griffin D, Chengappa MM, Kuszak J, et al. Bacterial pathogens of the bovine respiratory disease complex. Vet Clin North Am Food Anim Pract. 2010;26(2):381-394.

[3] Highlander SK. Molecular genetic analysis of virulence in Mannheimia (Pasteurella) haemolytica. Front Biosci. 2001;6:D1128-D1150.

[4] Paulsen DB, Confer AW, Clinkenbeard KD, et al. Lipopolysaccharide from Pasteurella haemolytica and Escherichia coli stimulate differential responses in bovine alveolar macrophages. Vet Immunol Immunopathol. 1995;47(3-4):259-274.

[5] Gioia J, Qin X, Jiang H, et al. The genome sequence of Mannheimia haemolytica A1: insights into virulence, natural competence, and Pasteurellaceae phylogeny. J Bacteriol. 2006;188(20):7257-7266.

[6] Confer AW, Ayalew S. The Mannheimia haemolytica leukotoxin: a virulence factor and target for vaccine development. Anim Health Res Rev. 2013;14(2):91-105.

[7] Welsh RD, Dye LB, Payton ME, et al. Isolation and antimicrobial susceptibilities of bacterial pathogens from bovine pneumonia: 1994-2002. J Vet Diagn Invest. 2004;16(5):426-431.

[8] Harper M, Boyce JD, Adler B. Pasteurella multocida pathogenesis: 125 years after Pasteur. FEMS Microbiol Lett. 2006;265(1):1-10.

[9] Pullinger GD, Bevir T, Lax AJ. The Pasteurella multocida toxin interacts with signalling pathways to perturb cell growth and differentiation. Int J Med Microbiol. 2004;293(7-8):505-512.

[10] Mizan S, Henk A, Stallings A, et al. Cloning and characterization of sialidases with 2-6 and 2-3 sialyl specificity from Pasteurella multocida. J Bacteriol. 2000;182(24):6874-6883.

[11] Lubbers BV, Hanzlicek GA, Burciaga-Robles LO, et al. Antimicrobial susceptibility of Pasteurella multocida isolates from bovine respiratory disease cases in the United States. J Vet Diagn Invest. 2017;29(4):500-504.

[12] Nicholas RAJ, Ayling RD. Mycoplasma bovis: disease, diagnosis, and control. Res Vet Sci. 2003;74(2):105-112.

[13] Gautier-Bouchardon AV, Ferré S, Le Grand D, et al. Overall decrease in the susceptibility of Mycoplasma bovis isolates to gamithromycin over a 10-year period in France. J Antimicrob Chemother. 2014;69(6):1549-1554.

[14] Lysnyansky I, Sachse K, Rosenbusch R, et al. The vsp locus of Mycoplasma bovis: gene organization and structural features. J Bacteriol. 1999;181(18):5734-5741.

[15] Perez-Casal J, Prysliak T. Detection of antibodies against Mycoplasma bovis in bovine serum using a recombinant VspA fragment. Vet Microbiol. 2007;123(1-3):135-142.

[16] Bischof DF, Janis C, Vilei EM, et al. Cytotoxicity of Mycoplasma bovis towards bovine monocytes is not mediated by hydrogen peroxide. Vet Microbiol. 2008;130(1-2):120-128.

[17] Gondaira S, Higuchi H, Iwano H, et al. Mycoplasma bovis escapes bovine neutrophil extracellular traps. Vet Microbiol. 2018;224:72-78.

[18] Shah MK, Maunsell FP, Donovan GA, et al. Pathology of Mycoplasma bovis pneumonia in cattle. Vet Pathol. 2001;38(6):652-659.

[19] Godinho KS. A meta-analysis of antimicrobial susceptibility profiles of Mannheimia haemolytica and Pasteurella multocida isolates from cattle in Europe and North America. J Vet Pharmacol Ther. 2008;31(4):299-307.

[20] Stipkovits L, Ripley PH, Tenk M, et al. The efficacy of valnemulin (Econor) in the control of enzootic pneumonia in pigs. Vet Rec. 2001;149(22):678-681.

[21] McAuliffe L, Ellis RJ, Ayling RD, et al. Biofilm formation by mycoplasma species and its role in environmental persistence and survival. Microbiology. 2006;152(Pt 4):913-922.

[22] Horwood PF, Mahony TJ. Multiplex and broadly reactive PCR assays for the detection of bacterial and viral pathogens of the bovine respiratory disease complex. J Virol Methods. 2008;152(1-2):1-7.

[23] Timsit E, Halimi M, Assié S, et al. Evaluation of a real-time PCR assay for the detection and quantification of Mannheimia haemolytica in nasal swabs of cattle. J Vet Diagn Invest. 2010;22(1):11-17.

[24] Taylor JD, Fulton RW, Lehenbauer TW, et al. Comparison of real-time PCR, conventional PCR, and culture for detection of Mannheimia haemolytica and Pasteurella multocida from bovine bronchoalveolar lavage fluid. J Vet Diagn Invest. 2010;22(2):233-237.

[25] Amram E, Mikula I, Lysnyansky I, et al. Characterization of the Mycoplasma bovis isolate involved in the first documented outbreak of mycoplasma pneumonia in Israeli cattle. Isr J Vet Med. 2016;71(1):48-54.

[26] Klima CL, Zaheer R, Cook SR, et al. A multiplex PCR assay for the detection of bacterial pathogens of the bovine respiratory disease complex. J Vet Diagn Invest. 2014;26(3):381-391.

[27] Gagea MI, Bateman KG, van Dreumel T, et al. Diseases and pathogens associated with mortality in Ontario beef feedlots. J Vet Diagn Invest. 2006;18(3):247-256.

[28] Booker CW, Abutarbush SM, Morley PS, et al. Comparison of deep nasopharyngeal swab and bronchoalveolar lavage fluid for detection of respiratory pathogens in feedlot calves with undifferentiated respiratory disease. Can Vet J. 2008;49(5):465-470.

[29] Anholt RM, Klima C, Allan N, et al. Antimicrobial susceptibility of Mannheimia haemolytica and Pasteurella multocida isolated from bovine respiratory disease cases in Canada. Can J Vet Res. 2017;81(3):189-197.

[30] Lubbers BV, Hanzlicek GA. Antimicrobial resistance in Histophilus somni and Mycoplasma bovis from bovine respiratory disease cases in the United States. J Vet Diagn Invest. 2020;32(6):836-841.

[31] Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. 5th ed. CLSI supplement VET01S. Wayne, PA; 2020.

[32] Portis E, Lindeman C, Johansen L, et al. A ten-year (2000-2009) study of antimicrobial susceptibility of bacteria that cause bovine respiratory disease complex in the United States. J Vet Diagn Invest. 2012;24(4):700-707.

[33] DeDonder KD, Gehring R, Lubbers BV, et al. A review of antimicrobial resistance in Mannheimia haemolytica and Pasteurella multocida from North American cattle. J Vet Intern Med. 2016;30(4):1314-1325.

[34] Andrés-Lasheras S, Jelinski M, Zaheer R, et al. Bovine respiratory disease in western Canada: a genomic epidemiological perspective of Mannheimia haemolytica and Pasteurella multocida. Microb Genom. 2022;8(6):000843.

[35] Gautier-Bouchardon AV, Ferré S, Le Grand D, et al. In vitro antimicrobial susceptibility of Mycoplasma bovis field isolates in France. Vet Microbiol. 2015;179(3-4):281-287.

[36] Cameron A, Klima CL, Zaheer R, et al. Whole-genome sequencing of Mannheimia haemolytica and Pasteurella multocida from bovine respiratory disease complex cases in the USA and Canada. Microb Genom. 2020;6(10):000433.

[37] Hällemar M, Fuxelius HH, Björkman J, et al. Genomic analysis of Mycoplasma bovis isolates from a Swedish cattle herd reveals the presence of two distinct clonal lineages. Vet Microbiol. 2020;247:108783.

[38] Timsit E, Le Guillou J, Vallet JL, et al. Genomic characterization of antimicrobial resistance in Mannheimia haemolytica isolated from bovine respiratory disease in France. J Antimicrob Chemother. 2021;76(4):940-949.

[39] Smith RA. Impact of disease on feedlot performance: a review. J Anim Sci. 1998;76(1):272-274.

[40] Nickell JS, White BJ. Metaphylactic antimicrobial therapy for bovine respiratory disease in stocker and feedlot cattle. Vet Clin North Am Food Anim Pract. 2010;26(2):285-301.

[41] Abell KM, Theurer ME, Larson RL, et al. Evaluation of a risk-scoring system for prediction of bovine respiratory disease in feedlot cattle. J Anim Sci. 2017;95(Suppl 4):96-97.

[42] Mosier D, Confer AW, Panciera RJ. The evolution of vaccines for bovine pneumonic pasteurellosis. Vet Med. 1998;93:457-464.

[43] Soehnlen MK, Aydin A, Lengerich EJ, et al. Blinded, controlled field trial of two commercially available Mycoplasma bovis vaccines. Vaccine. 2011;29(33):5346-5351.

[44] Maunsell FP, Woolums AR, Francoz D, et al. Mycoplasma bovis infections in cattle. J Vet Intern Med. 2011;25(4):772-783.

[45] Caswell JL, Bateman KG, Cai HY, et al. Mycoplasma bovis in respiratory disease of feedlot cattle. Vet Clin North Am Food Anim Pract. 2010;26(2):319-330.

[46] Fulton RW, Blood KS, Panciera RJ, et al. Lung pathology and infectious agents in fatal feedlot pneumonias and relationship with mortality, feedlot performance, and carcass traits. J Vet Diagn Invest. 2009;21(6):802-809.

[47] Booker CW, Wildman BK, Jim GK, et al. Microbiological and histopathological findings in fatal respiratory disease in feedlot cattle. Can Vet J. 1997;38(10):623-627.

[48] Griffin D. Economic impact associated with respiratory disease in beef cattle. Vet Clin North Am Food Anim Pract. 1997;13(3):367-377.

[49] Snowder GD, Van Vleck LD, Cundiff LV, et al. Influence of breed, heterosis, and disease on feedlot performance and carcass traits of beef steers. J Anim Sci. 2006;84(2